1 | percent | 12,896 |
2 | fold | 902 |
3 | milliliters | 58 |
4 | percents | 24 |
5 | percentage-point | 11 |
6 | grammes | 7 |
7 | ltss | 3 |
8 | mites/g | 3 |
9 | months-not | 3 |
10 | puffiness | 3 |
11 | subkebeles | 3 |
12 | year-one | 3 |
13 | cigarettes/day-no | 2 |
14 | eight-hr | 2 |
15 | g.p.s | 2 |
16 | icnarc | 2 |
17 | lgrf | 2 |
18 | lsvs | 2 |
19 | min/kg | 2 |
20 | mm/d | 2 |
21 | ms/unit | 2 |
22 | mw/g | 2 |
23 | overweight-obese | 2 |
24 | picomole | 2 |
25 | platelets/ml | 2 |
26 | ppargc1b | 2 |
27 | rygb-patients | 2 |
28 | uida | 2 |
29 | €/kg | 2 |
30 | 1.1,1.3 | 1 |
31 | 1.3,1.4 | 1 |
32 | 132.2±2.1 | 1 |
33 | 2.1±2.4 | 1 |
34 | 3-aryl-4-acyloxyethoxyfuran-2 | 1 |
35 | 3.5-year-olds | 1 |
36 | 378.95 | 1 |
37 | 383±82 | 1 |
38 | 4.0±0.1 | 1 |
39 | 54-wk-old | 1 |
40 | 7-weeks-old | 1 |
41 | aceclofenac- | 1 |
42 | aes/y | 1 |
43 | biflavones | 1 |
44 | blackbucks | 1 |
45 | breath-units | 1 |
46 | bromoadenosine | 1 |
47 | bromoguanosine | 1 |
48 | bushels | 1 |
49 | bvts | 1 |
50 | ccm-related | 1 |
51 | cpr-i/cs | 1 |
52 | elite-standard | 1 |
53 | expert-years | 1 |
54 | fatteners | 1 |
55 | flindersi | 1 |
56 | genotyping-adjusted | 1 |
57 | gy-equivalent | 1 |
58 | g·h-1 | 1 |
59 | hanarostent | 1 |
60 | have-de | 1 |
61 | hepatoblastomas | 1 |
62 | heterohybridomas | 1 |
63 | hyalinum | 1 |
64 | indicated-referral | 1 |
65 | ivorine | 1 |
66 | laparostomies | 1 |
67 | left-bbb | 1 |
68 | male-partners | 1 |
69 | mb-duplication | 1 |
70 | mg/mdl | 1 |
71 | ml/100g | 1 |
72 | ms-one | 1 |
73 | n-acryloyl/n-cinnamoyl | 1 |
74 | nonviremic | 1 |
75 | norouz | 1 |
76 | patient/months | 1 |
77 | plr-δ | 1 |
78 | post-hygiene | 1 |
79 | powerlifters | 1 |
80 | redislocations | 1 |
81 | sbp/dbd | 1 |
82 | segment-model | 1 |
83 | single-mothers | 1 |
84 | slovenska | 1 |
85 | triiodothyronine-nonsuppressible | 1 |
86 | unit-periods | 1 |
87 | vas=1.22±1.77 | 1 |
88 | vas=1.68±2.21 | 1 |
89 | years.meta-analyses | 1 |
1 | 1.1,1.3 | 1 |
2 | 1.3,1.4 | 1 |
3 | 132.2±2.1 | 1 |
4 | 2.1±2.4 | 1 |
5 | 3-aryl-4-acyloxyethoxyfuran-2 | 1 |
6 | 3.5-year-olds | 1 |
7 | 378.95 | 1 |
8 | 383±82 | 1 |
9 | 4.0±0.1 | 1 |
10 | 54-wk-old | 1 |
11 | 7-weeks-old | 1 |
12 | aceclofenac- | 1 |
13 | aes/y | 1 |
14 | biflavones | 1 |
15 | blackbucks | 1 |
16 | breath-units | 1 |
17 | bromoadenosine | 1 |
18 | bromoguanosine | 1 |
19 | bushels | 1 |
20 | bvts | 1 |
21 | ccm-related | 1 |
22 | cigarettes/day-no | 2 |
23 | cpr-i/cs | 1 |
24 | eight-hr | 2 |
25 | elite-standard | 1 |
26 | expert-years | 1 |
27 | fatteners | 1 |
28 | flindersi | 1 |
29 | fold | 902 |
30 | g.p.s | 2 |
31 | genotyping-adjusted | 1 |
32 | grammes | 7 |
33 | gy-equivalent | 1 |
34 | g·h-1 | 1 |
35 | hanarostent | 1 |
36 | have-de | 1 |
37 | hepatoblastomas | 1 |
38 | heterohybridomas | 1 |
39 | hyalinum | 1 |
40 | icnarc | 2 |
41 | indicated-referral | 1 |
42 | ivorine | 1 |
43 | laparostomies | 1 |
44 | left-bbb | 1 |
45 | lgrf | 2 |
46 | lsvs | 2 |
47 | ltss | 3 |
48 | male-partners | 1 |
49 | mb-duplication | 1 |
50 | mg/mdl | 1 |
51 | milliliters | 58 |
52 | min/kg | 2 |
53 | mites/g | 3 |
54 | ml/100g | 1 |
55 | mm/d | 2 |
56 | months-not | 3 |
57 | ms-one | 1 |
58 | ms/unit | 2 |
59 | mw/g | 2 |
60 | n-acryloyl/n-cinnamoyl | 1 |
61 | nonviremic | 1 |
62 | norouz | 1 |
63 | overweight-obese | 2 |
64 | patient/months | 1 |
65 | percent | 12,896 |
66 | percentage-point | 11 |
67 | percents | 24 |
68 | picomole | 2 |
69 | platelets/ml | 2 |
70 | plr-δ | 1 |
71 | post-hygiene | 1 |
72 | powerlifters | 1 |
73 | ppargc1b | 2 |
74 | puffiness | 3 |
75 | redislocations | 1 |
76 | rygb-patients | 2 |
77 | sbp/dbd | 1 |
78 | segment-model | 1 |
79 | single-mothers | 1 |
80 | slovenska | 1 |
81 | subkebeles | 3 |
82 | triiodothyronine-nonsuppressible | 1 |
83 | uida | 2 |
84 | unit-periods | 1 |
85 | vas=1.22±1.77 | 1 |
86 | vas=1.68±2.21 | 1 |
87 | year-one | 3 |
88 | years.meta-analyses | 1 |
89 | €/kg | 2 |
1 | aceclofenac- | 1 |
2 | g·h-1 | 1 |
3 | 4.0±0.1 | 1 |
4 | 132.2±2.1 | 1 |
5 | vas=1.68±2.21 | 1 |
6 | 3-aryl-4-acyloxyethoxyfuran-2 | 1 |
7 | 383±82 | 1 |
8 | 1.1,1.3 | 1 |
9 | 1.3,1.4 | 1 |
10 | 2.1±2.4 | 1 |
11 | 378.95 | 1 |
12 | vas=1.22±1.77 | 1 |
13 | uida | 2 |
14 | slovenska | 1 |
15 | ppargc1b | 2 |
16 | left-bbb | 1 |
17 | nonviremic | 1 |
18 | icnarc | 2 |
19 | mm/d | 2 |
20 | sbp/dbd | 1 |
21 | ccm-related | 1 |
22 | genotyping-adjusted | 1 |
23 | 54-wk-old | 1 |
24 | 7-weeks-old | 1 |
25 | fold | 902 |
26 | elite-standard | 1 |
27 | have-de | 1 |
28 | triiodothyronine-nonsuppressible | 1 |
29 | picomole | 2 |
30 | post-hygiene | 1 |
31 | ivorine | 1 |
32 | bromoguanosine | 1 |
33 | bromoadenosine | 1 |
34 | year-one | 3 |
35 | ms-one | 1 |
36 | overweight-obese | 2 |
37 | lgrf | 2 |
38 | mites/g | 3 |
39 | mw/g | 2 |
40 | ml/100g | 1 |
41 | min/kg | 2 |
42 | €/kg | 2 |
43 | flindersi | 1 |
44 | indicated-referral | 1 |
45 | mg/mdl | 1 |
46 | segment-model | 1 |
47 | platelets/ml | 2 |
48 | n-acryloyl/n-cinnamoyl | 1 |
49 | hyalinum | 1 |
50 | mb-duplication | 1 |
51 | cigarettes/day-no | 2 |
52 | eight-hr | 2 |
53 | g.p.s | 2 |
54 | heterohybridomas | 1 |
55 | hepatoblastomas | 1 |
56 | cpr-i/cs | 1 |
57 | 3.5-year-olds | 1 |
58 | unit-periods | 1 |
59 | laparostomies | 1 |
60 | subkebeles | 3 |
61 | grammes | 7 |
62 | biflavones | 1 |
63 | years.meta-analyses | 1 |
64 | patient/months | 1 |
65 | blackbucks | 1 |
66 | bushels | 1 |
67 | redislocations | 1 |
68 | expert-years | 1 |
69 | single-mothers | 1 |
70 | fatteners | 1 |
71 | male-partners | 1 |
72 | powerlifters | 1 |
73 | milliliters | 58 |
74 | puffiness | 3 |
75 | ltss | 3 |
76 | breath-units | 1 |
77 | percents | 24 |
78 | rygb-patients | 2 |
79 | bvts | 1 |
80 | lsvs | 2 |
81 | ms/unit | 2 |
82 | percent | 12,896 |
83 | gy-equivalent | 1 |
84 | hanarostent | 1 |
85 | percentage-point | 11 |
86 | months-not | 3 |
87 | aes/y | 1 |
88 | norouz | 1 |
89 | plr-δ | 1 |